A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis

Han Sun, Liqun Luo, Bachchu Lal, Xinrong Ma, Lieping Chen, Christine L. Hann, Amy M. Fulton, Daniel J. Leahy, John Laterra, Min Li

Research output: Contribution to journalArticle

Abstract

Two-pore domain potassium (K2P) channels act to maintain cell resting membrane potential - a prerequisite for many biological processes. KCNK9, a member of K2P family, is implicated in cancer, owing to its overexpression in human tumours and its ability to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here we describe the development of monoclonal antibodies against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding induces channel internalization. The addition of Y4 to KCNK9-expressing carcinoma cells reduces cell viability and increases cell death. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in mice. Evidence for Y4-mediated carcinoma cell autonomous and immune-dependent cytotoxicity is presented. Our study reveals that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9-expressing malignancies.

Original languageEnglish (US)
Article number10339
JournalNature Communications
Volume7
DOIs
StatePublished - Feb 4 2016

Fingerprint

Cell Survival
Monoclonal Antibodies
Neoplasm Metastasis
Carcinoma
Antibodies
Neoplasms
cancer
Castration
antibodies
Erythrasma
Potassium Channels
Biological Processes
Heterografts
Membrane Potentials
Lung Neoplasms
Cell Death
Cell Membrane
Breast Neoplasms
Contraception Behavior
metastasis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis. / Sun, Han; Luo, Liqun; Lal, Bachchu; Ma, Xinrong; Chen, Lieping; Hann, Christine L.; Fulton, Amy M.; Leahy, Daniel J.; Laterra, John; Li, Min.

In: Nature Communications, Vol. 7, 10339, 04.02.2016.

Research output: Contribution to journalArticle

Sun, Han; Luo, Liqun; Lal, Bachchu; Ma, Xinrong; Chen, Lieping; Hann, Christine L.; Fulton, Amy M.; Leahy, Daniel J.; Laterra, John; Li, Min / A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis.

In: Nature Communications, Vol. 7, 10339, 04.02.2016.

Research output: Contribution to journalArticle

@article{40bf9a1a700047e8a0b5ecd8f0c51506,
title = "A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis",
abstract = "Two-pore domain potassium (K2P) channels act to maintain cell resting membrane potential - a prerequisite for many biological processes. KCNK9, a member of K2P family, is implicated in cancer, owing to its overexpression in human tumours and its ability to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here we describe the development of monoclonal antibodies against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding induces channel internalization. The addition of Y4 to KCNK9-expressing carcinoma cells reduces cell viability and increases cell death. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in mice. Evidence for Y4-mediated carcinoma cell autonomous and immune-dependent cytotoxicity is presented. Our study reveals that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9-expressing malignancies.",
author = "Han Sun and Liqun Luo and Bachchu Lal and Xinrong Ma and Lieping Chen and Hann, {Christine L.} and Fulton, {Amy M.} and Leahy, {Daniel J.} and John Laterra and Min Li",
year = "2016",
month = "2",
doi = "10.1038/ncomms10339",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis

AU - Sun,Han

AU - Luo,Liqun

AU - Lal,Bachchu

AU - Ma,Xinrong

AU - Chen,Lieping

AU - Hann,Christine L.

AU - Fulton,Amy M.

AU - Leahy,Daniel J.

AU - Laterra,John

AU - Li,Min

PY - 2016/2/4

Y1 - 2016/2/4

N2 - Two-pore domain potassium (K2P) channels act to maintain cell resting membrane potential - a prerequisite for many biological processes. KCNK9, a member of K2P family, is implicated in cancer, owing to its overexpression in human tumours and its ability to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here we describe the development of monoclonal antibodies against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding induces channel internalization. The addition of Y4 to KCNK9-expressing carcinoma cells reduces cell viability and increases cell death. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in mice. Evidence for Y4-mediated carcinoma cell autonomous and immune-dependent cytotoxicity is presented. Our study reveals that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9-expressing malignancies.

AB - Two-pore domain potassium (K2P) channels act to maintain cell resting membrane potential - a prerequisite for many biological processes. KCNK9, a member of K2P family, is implicated in cancer, owing to its overexpression in human tumours and its ability to promote neoplastic cell survival and growth. However, KCNK9's underlying contributions to malignancy remain elusive due to the absence of specific modulators. Here we describe the development of monoclonal antibodies against the KCNK9 extracellular domain and their functional effects. We show that one antibody (Y4) with the highest affinity binding induces channel internalization. The addition of Y4 to KCNK9-expressing carcinoma cells reduces cell viability and increases cell death. Systemic administration of Y4 effectively inhibits growth of human lung cancer xenografts and murine breast cancer metastasis in mice. Evidence for Y4-mediated carcinoma cell autonomous and immune-dependent cytotoxicity is presented. Our study reveals that antibody-based KCNK9 targeting is a promising therapeutic strategy in KCNK9-expressing malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84957599439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957599439&partnerID=8YFLogxK

U2 - 10.1038/ncomms10339

DO - 10.1038/ncomms10339

M3 - Article

VL - 7

JO - Nature Communications

T2 - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10339

ER -